Comparison of different tumour promoters and bryostatin 1 on protein kinase C activation and down-regulation in rat renal mesangial cells.
The effects of a series of protein kinase C (PKC) activators with different spectra of biological activities and reportedly different patterns of PKC isoenzyme activation were examined in renal mesangial cells. Treatment of mesangial cells with the tumor promoters phorbol 12-myristate 13-acetate (PMA), debromoaplysiatoxin, dihydroteleocidin and thymeleatoxin, as well as with the marine natural product bryostatin 1, caused translocation and at least partial down-regulation of the PKC-alpha, -delta and -epsilon isoenzymes as assessed by immunoblot analysis. Bryostatin 1 mediates a faster depletion of PKC-alpha isoform than any of the other PKC activators. Thymeleatoxin, which has been reported to selectively activate PKC-alpha, -beta and -gamma, but not PKC-delta or -epsilon isoenzymes in vitro, turned out to exert the most potent effect on PKC-delta and -epsilon in mesangial cells and down-regulated these isotypes within 8-24 hr. None of the compounds tested affected cellular distribution or amount of PKC-zeta in mesangial cells. Thus, all of the PKC activators tested are able to translocate and down-regulate three of the four PKC isoenzymes present in mesangial cells although with different kinetics. All PKC activators stimulated a phospholipase A2-mediated arachidonic acid release, a phospholipase D-mediated phosphatidylcholine hydrolysis, a comparable small proliferative response and an inhibition of phospholipase C-mediated inositol trisphosphate generation. These results suggest: (i) that the PKC activators investigated in this study do not display any type of isotype-specificity that could be used to selectively activate or down-regulate PKC isoenzymes in intact cell-systems; (ii) that thymeleatoxin has a different isoenzyme selectivity in intact cells as compared to in vitro enzyme inhibition data; and (iii) PKC-zeta is resistant to all PKC activators investigated in this study.
Huwiler
A
A
Department of Pharmacology, University of Basel, Switzerland.
Fabbro
D
D
Pfeilschifter
J
J
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D054713:Bryostatins; D002273:Carcinogens / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D015536:Down-Regulation; D004789:Enzyme Activation / Q000187:drug effects; D005920:Glomerular Mesangium / Q000187:drug effects*; D007527:Isoenzymes / Q000378:metabolism; D007783:Lactones / Q000494:pharmacology*; D018942:Macrolides; D010739:Phospholipase D / Q000378:metabolism; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011493:Protein Kinase C / Q000378:metabolism*; D051381:Rats; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors
D054713:Bryostatins; D002273:Carcinogens; D007527:Isoenzymes; D007783:Lactones; D018942:Macrolides; D000804:Angiotensin II; C046785:bryostatin 1; D011493:Protein Kinase C; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D010739:Phospholipase D